← Leaderboards
Carolyn Russo
University Of California San Francisco
$86,512
Attributed
$86,512
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$86,512 · 4
By mechanism
M01$86,512 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Katherine Kurshan Matthay$7,757,759
- Kevin M Shannon$44,683,939
- Michael D Prados$7,364,703
- James Feusner$34,914
- Neal L Benowitz$31,329,042
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationNeoplasm /Cancer ChemotherapyClinical ResearchHuman SubjectBrain NeoplasmsPediatric Neoplasm /CancerChild (0-11)Injection /InfusionDrug Screening /EvaluationClinical Trial Phase IAntineoplasticsTopotecanCentral Nervous System NeoplasmsDosageDrug Administration RoutesEtoposideNeoplasm /Cancer PharmacologyOral AdministrationPharmacokineticsPhenylacetatesPhenylcarboxylate
Grant awards (20)
PHASE II STUDY OF ORAL ETOPOSIDE IN CHILDREN WITH RECURRENT BRAIN TUMORS$0
M01 · FY2002 · RR
PHASE I STUDY OF INTRATHECAL TOPOTECAN$0
M01 · FY2002 · RR
PHENYLBUTYRATE CONTINUOUS INFUSION IN CHILDREN W/ REFRACTORY MALIGNANCY$0
M01 · FY2002 · RR
PHENYLACETATE IN PEDIATRIC PATIENTS W/ CENTRAL NERVOUS SYSTEM TUMORS$0
M01 · FY2002 · RR
PHASE II STUDY OF ORAL ETOPOSIDE IN CHILDREN WITH RECURRENT BRAIN TUMORS$0
M01 · FY2001 · RR
PHASE I STUDY OF INTRATHECAL TOPOTECAN$0
M01 · FY2001 · RR
PHENYLBUTYRATE CONTINUOUS INFUSION IN CHILDREN W/ REFRACTORY MALIGNANCY$0
M01 · FY2001 · RR
PHENYLACETATE IN PEDIATRIC PATIENTS W/ CENTRAL NERVOUS SYSTEM TUMORS$0
M01 · FY2001 · RR
PHASE II STUDY OF ORAL ETOPOSIDE IN CHILDREN WITH RECURRENT BRAIN TUMORS$25,799
M01 · FY2000 · RR
PHASE I STUDY OF INTRATHECAL TOPOTECAN$25,799
M01 · FY2000 · RR
PHENYLBUTYRATE CONTINUOUS INFUSION IN CHILDREN W/ REFRACTORY MALIGNANCY$17,457
M01 · FY2000 · RR
PHENYLACETATE IN PEDIATRIC PATIENTS W/ CENTRAL NERVOUS SYSTEM TUMORS$17,457
M01 · FY2000 · RR
PHENYLACETATE IN PEDIATRIC PATIENTS W/ CENTRAL NERVOUS SYSTEM TUMORS$0
M01 · FY2000 · RR
PHASE II STUDY OF ORAL ETOPOSIDE IN CHILDREN WITH RECURRENT BRAIN TUMORS$0
M01 · FY2000 · RR
PHASE I STUDY OF INTRATHECAL TOPOTECAN$0
M01 · FY2000 · RR
PHASE I STUDY OF INTRATHECAL TOPOTECAN$0
M01 · FY2000 · RR
PHENYLBUTYRATE CONTINUOUS INFUSION IN CHILDREN W/ REFRACTORY MALIGNANCY$0
M01 · FY2000 · RR
PHENYLBUTYRATE CONTINUOUS INFUSION IN CHILDREN W/ REFRACTORY MALIGNANCY$0
M01 · FY2000 · RR
PHASE II STUDY OF ORAL ETOPOSIDE IN CHILDREN WITH RECURRENT BRAIN TUMORS$0
M01 · FY2000 · RR
PHENYLACETATE IN PEDIATRIC PATIENTS W/ CENTRAL NERVOUS SYSTEM TUMORS$0
M01 · FY2000 · RR